ライフサイエンスコーパス: autologous transplantation

1 rative medicine, given their feasibility for autologous transplantation.

2 3, and 48% of patients had undergone a prior autologous transplantation.

3 cies, and ex vivo purging of cancer cells in autologous transplantation.

4 es them impractical for surgical removal and autologous transplantation.

5 of patients with germ cell tumors undergoing autologous transplantation.

6 patients received melphalan 200 mg/m(2) with autologous transplantation.

7 tic syndromes (MDS) have been reported after autologous transplantation.

8 sufficient numbers of normal stem cells for autologous transplantation.

9 n chemotherapy and three after allogeneic or autologous transplantation.

10 amyloidosis who meet functional criteria for autologous transplantation.

11 normal PBSCs could be collected and used for autologous transplantation.

12 tute the hematopoietic compartment following autologous transplantation.

13 ocytic cells resistant to HIV-1 growth after autologous transplantation.

14 tation or use of ANK to purge CML marrow for autologous transplantation.

15 ion in functional HSCs within the context of autologous transplantation.

16 -cell manufacturing and 7 months earlier for autologous transplantation.

17 ed in vivo from HBB-corrected HSCs following autologous transplantation.

18 of pulp-dentin regeneration in vivo through autologous transplantation.

19 oma naive or myeloma experienced to simulate autologous transplantation.

20 C expansion and lineage commitment following autologous transplantation.

21 prognostic impact of del(13) observed after autologous transplantation.

22 ration as consolidation therapy after double autologous transplantation.

23 cal to validate their in vivo fate following autologous transplantation.

24 experienced treatment failure with previous autologous transplantation.

25 plications, as these cells could be used for autologous transplantation.

26 tiuxetan was followed by high-dose BEAM and autologous transplantation.

27 ted with rituximab-induced neutropenia after autologous transplantation.

28 ed DLBCL should be considered for RIT versus autologous transplantation.

29 reviously experienced treatment failure with autologous transplantation.

30 ized to chemotherapy for 2.5 years versus an autologous transplantation.

31 was administered a median of 3 months before autologous transplantation.

32 ived allogeneic marrow and one had undergone autologous transplantation.

33 bination of ex vivo genetic manipulation and autologous transplantation.

34 who experience disease recurrence following autologous transplantation.

35 ts (56%) entered into the study proceeded to autologous transplantation.

36 There may be a benefit to graft purging in autologous transplantation.

37 worse for those who had previously undergone autologous transplantation.

38 ransplantations, whereas 162 (99%) performed autologous transplantations.

39 of intensive chemotherapy (117 patients) or autologous transplantation (115 patients).

40 her 5-year OS (46%) than those randomized to autologous transplantation (37%; P = .03).

41 remission therapies: intensive chemotherapy, autologous transplantation (ABMT), or allogeneic bone ma

42 Following autologous transplantation, all three patients exhibited

43 Compared with autologous transplantation, allogeneic PBPC transplantat

44 allogeneic transplantation (auto/RICallo) to autologous transplantation alone (auto).

45 arrow function is similar to that seen after autologous transplantation and does not carry the risk f

46 be safely combined with high-dose BEAM with autologous transplantation and has the potential to be m

47 tion between lymphocyte count recovery after autologous transplantation and overall survival has been

48 ing the potential utility of these cells for autologous transplantation and possible diagnostic testi

49 are not inherently immunologically inert for autologous transplantation and suggest that iPSC-derived

50 nduction regimen and the potential roles for autologous transplantation and/or rituximab maintenance.

51 pse after disease recurrence following prior autologous transplantation, and 51 patients at high risk

52 Allogeneic SCT, autologous transplantation, and consolidation chemothera

53 l transplantation, tumor cell purging before autologous transplantation, and ex vivo cultures used fo

54 tal of 36 patients were studied (29 received autologous transplantation, and seven received allogenei

55 g as the graft of choice in many centers for autologous transplantation, and with increasing frequenc

56 High-dose melphalan followed by autologous transplantation appears effective for improvi

57 Autologous transplantation appears to offer a modest sur

58 ith A + G had at least a 90% success rate of autologous transplantation as assessed by neutrophil eng

59 conventional chemotherapy support the use of autologous transplantation as salvage therapy if such pa

60 it from early treatment intensification with autologous transplantation, as indicated by the possibil

61 therapy and would not have been eligible for autologous transplantation at most centers.

62 d one (n = 13) or two or more (n = 17) prior autologous transplantations (ATs).

63 ent stem cells (iPSC) may be administered by autologous transplantation, avoiding immunologic challen

64 gene addition and gene editing, followed by autologous transplantation back to the patient.

65 nts who were treated uniformly with a tandem autologous transplantation-based protocol and were evalu

66 ecome the preferred source of stem cells for autologous transplantation because of the technical adva

67 We conclude that both allogeneic and autologous transplantation can induce durable remissions

68 Autologous transplantation can prolong event-free and po

69 Autologous transplantation can prolong overall survival

70 There is no evidence that a single autologous transplantation can replace consolidation/mai

71 ant event-free survival advantage to upfront autologous transplantation compared with interferon main

72 erived haematopoietic stem cells followed by autologous transplantation could be used to cure beta-ha

73 eed for rapid disease control, candidacy for autologous transplantation, cytopenias, IgM-related comp

74 Only the four patients treated after prior autologous transplantation developed acute GVHD (P =.000

75 Prior autologous transplantation failed in five (28%) patients

76 y pure populations of CD34+ marrow cells for autologous transplantation feasible.

77 g the most active drugs, in combination with autologous transplantation followed by maintenance thera

78 Autologous transplantation followed by treatment with CT

79 eukemic stem cells that may be beneficial in autologous transplantation for CML and perhaps other leu

80 e prove to be an extremely useful adjunct in autologous transplantation for CML.

81 les from 12 patients who developed TMN after autologous transplantation for Hodgkin lymphoma or non-H

82 focuses on recent advances in allogeneic and autologous transplantation for mantle cell lymphoma.

83 , from $36 000 to $88 000 (USD) for a single autologous transplantation for the initial hospitalizati

84 the chemotherapy group as compared with the autologous-transplantation group was 0.81 (P = 0.20 by t

85 as compared with 38 +/- 6.4 percent for the autologous-transplantation group; and the relative risk

86 ymphoma who experience a recurrence after an autologous transplantation has been considered a hazardo

87 High-dose melphalan supported by autologous transplantation has been the standard of care

88 reduce relapse of non-Hodgkin lymphoma after autologous transplantation have included ex vivo stem ce

89 an of five lines of prior therapy, including autologous transplantation in 69%, and 17% of patients w

90 ontribute to multilineage repopulation after autologous transplantation in a clinically relevant larg

91 dopamine neurons for up to 2 years following autologous transplantation in a Parkinson's disease (PD)

92 rgue that CD44 blockade may be beneficial in autologous transplantation in CML.

93 Particular emphasis is placed on the role of autologous transplantation in first complete remission,

94 in PBSC confers increased risk of t-MN after autologous transplantation in male but not female patien

95 dies comparing allogeneic transplantation to autologous transplantation in multiple myeloma is few an

96 To improve survival of tandem autologous transplantation in multiple myeloma, the seco

97 Autologous transplantation in myeloma can prolong surviv

98 te the outcome of high-dose chemotherapy and autologous transplantation in patients with diffuse B-ce

99 ell (PBC) rescue has become the mainstay for autologous transplantation in patients with lymphoma, mu

100 primitive progenitors to hematopoiesis after autologous transplantation in the rhesus macaque model.

101 tem cells in up to 10% of donors, precluding autologous transplantation in those donors or substantia

102 use of a short consolidation treatment after autologous transplantation increases the complete respon

103 Autologous transplantation is increasingly used to treat

104 rrow (BM), followed by ex vivo expansion for autologous transplantation may be less morbid, and more

105 om had progression of disease after previous autologous transplantation (median age 32 years [range 1

106 developed a competitive rhesus macaque (RM) autologous transplantation model, co-infusing HSCs trans

107 ended our observations to a nonhuman primate autologous transplantation model.

108 Although autologous transplantation obviates the risk of graft-ve

109 Autologous transplantation of 10(7) NA/CD31+ MNCs, 10(7)

110 111, lovotibeglogene autotemcel) consists of autologous transplantation of a patient's hematopoietic

111 111, lovotibeglogene autotemcel) consists of autologous transplantation of a patient's hematopoietic

112 Autologous transplantation of adipose tissue-derived mes

113 Effective therapies for AGA include autologous transplantation of androgen-resistant occipit

114 Autologous transplantation of bone marrow stem cells tha

115 itical aspects of vascular repair, including autologous transplantation of bone marrow-derived stem c

116 ironment poses additional challenges for the autologous transplantation of cells.

117 Autologous transplantation of conjunctiva and limbus are

118 Here we show that the autologous transplantation of EGCs into the brain of Abe

119 key that developed T-cell lymphoma following autologous transplantation of enriched bone marrow stem

120 Autologous transplantation of fecal microbiota of Ldlr(-

121 replacement therapy (ERT) is withheld before autologous transplantation of gamma-retroviral vector-tr

122 Autologous transplantation of gene-modified cells for tr

123 logeneic HSCT from CCR5-deficient donors and autologous transplantation of genetically modified hemat

124 In search for a better therapy, an autologous transplantation of hematopoietic progenitor c

125 111; lovotibeglogene autotemcel) consists of autologous transplantation of hematopoietic stem and pro

126 111; lovotibeglogene autotemcel) consists of autologous transplantation of hematopoietic stem and pro

127 from neutropenia following chemotherapy and autologous transplantation of hematopoietic stem and pro

128 Autologous transplantation of hematopoietic stem and pro

129 tients receiving high dose chemotherapy with autologous transplantation of hematopoietic stem cell pr

130 22 to 47) for patients randomly assigned to autologous transplantation of hematopoietic stem cells (

131 Here, we propose a one-time therapy through autologous transplantation of HSPCs genetically engineer

132 ere is considered to be a high potential for autologous transplantation of human dental pulp stem cel

133 ctions of impaired IP-DPSCs, suggesting that autologous transplantation of IFN-gamma-accelerated IP-D

134 st that an HIV vaccine might be delivered by autologous transplantation of in vitro-programmed HSPCs,

135 In this study, we report the first autologous transplantation of iPSCs in a large animal mo

136 underwent total body irradiation followed by autologous transplantation of marrow CD34 cells.

137 contribute to HIV cure through allogeneic or autologous transplantation of naturally occurring or eng

138 proach shows definitive engraftment by using autologous transplantation of noninjured recipients, our

139 total pancreatectomy were candidates for the autologous transplantation of pancreatic islet.

140 Autologous transplantation of patient-specific induced p

141 py has been developed as a method to perform autologous transplantations of a patient's own stem cell

142 cells (HSPCs) from FA patients, either after autologous transplantation or infusion into immunodefici

143 ent anti-inflammatory protocols for clinical autologous transplantation (P < 0.01).

144 al (P = .04) and specifically benefited from autologous transplantation (P = .006).

145 ing in 1994, based on encouraging results in autologous transplantation, patients (n = 81) were treat

146 The results of allogeneic and autologous transplantation preparative regimens, includi

147 patient cost in 1997 dollars was $55,500 for autologous transplantation (range, $28,200 to $148,200)

148 ped leukemia at an average of 16 months post-autologous transplantation (range, 11 to 21 months).

149 loma refractory to standard chemotherapy and autologous transplantation received a matched unrelated

150 oietic stem cells (HSCs) in combination with autologous transplantation represents a recent paradigm

151 s, with or without high-dose chemotherapy or autologous transplantation, revealed a correlation betwe

152 nity for their therapeutic application in an autologous transplantation setting.

153 Autologous transplantation should be considered in young

154 closer to their use in disease analysis and autologous transplantation strategies.

155 sing parameters derived from the analysis of autologous transplantation studies in glucose-6-phosphat

156 Autologous transplantation studies in non-human primates

157 imulation were applied to limiting-dilution, autologous-transplantation studies in cats heterozygous

158 In a retrospective autologous transplantation study conducted on 706 patien

159 ercent, P = 0.005) in the group treated with autologous transplantation than in the intensive-chemoth

160 ripotent stem cells enables standardized and autologous transplantation therapy for PD.

161 e a potential source of expandable cells for autologous transplantation to treat Parkinson's Disease

162 protocol that can promote the realization of autologous transplantation to treat PD patients with the

163 either control (KLH only) or Id-KLH vaccine, autologous transplantation, vaccine-specific costimulate

164 Prior autologous transplantation was associated with late chim

165 tients may receive intensive chemotherapy or autologous transplantation; we undertook this randomised

166 non-Hodgkin's lymphoma who were eligible for autologous transplantation were randomized to receive r-

167 honate use, and myeloma therapy, except more autologous transplantations were performed on patients i

168 ted poor outcomes with immunochemotherapy or autologous transplantation will be important in determin

169 Four years earlier, autologous transplantation with a higher melphalan dose

170 reated patients, 9 are currently alive after autologous transplantation with a minimum follow-up of 1

171 -infected pig-tailed macaques that underwent autologous transplantation with CCR5 gene editing.

172 Autologous transplantation with peripheral blood stem ce

173 ute lymphoblastic leukemia (ALL) and compare autologous transplantation with standard chemotherapy.

174 cells by use of antibodies in the setting of autologous transplantation, with emphasis on the emergin

175 generating unlimited quantities of cells for autologous transplantation, with potential application i

176 We report the ability to perform autologous transplantation without blood-product support